IRIS PubliCatt

Fabbiani, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.829
NA - Nord America 2.997
AS - Asia 611
AF - Africa 7
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 7.458
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.972
DE - Germania 1.187
SE - Svezia 586
IT - Italia 487
PL - Polonia 428
CN - Cina 425
FR - Francia 401
UA - Ucraina 325
IE - Irlanda 140
GB - Regno Unito 117
IN - India 93
FI - Finlandia 85
TR - Turchia 46
BE - Belgio 20
CA - Canada 20
IR - Iran 18
RU - Federazione Russa 13
HK - Hong Kong 11
JP - Giappone 8
EU - Europa 6
NL - Olanda 6
MX - Messico 5
BR - Brasile 4
CH - Svizzera 4
DK - Danimarca 4
AT - Austria 3
CZ - Repubblica Ceca 3
RO - Romania 3
BG - Bulgaria 2
EG - Egitto 2
ES - Italia 2
GR - Grecia 2
KR - Corea 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
EE - Estonia 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
KE - Kenya 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
MM - Myanmar 1
NG - Nigeria 1
PE - Perù 1
PK - Pakistan 1
SG - Singapore 1
UG - Uganda 1
Totale 7.458
Salva come PNG Salva come JPEG
Città #
Chandler 653
Kraków 426
Ashburn 264
Jacksonville 247
San Mateo 156
Dublin 138
New York 138
Nanjing 135
Ann Arbor 122
Milan 88
Dearborn 85
Nürnberg 83
Rome 76
Wilmington 76
Houston 74
Lawrence 71
Cattolica 66
Woodbridge 62
Nanchang 57
Lancaster 53
Redmond 50
Boston 48
Izmir 45
Redwood City 42
Shenyang 33
Seattle 32
Boardman 25
Bremen 25
Kunming 25
Verona 24
Changsha 23
Mountain View 23
Fairfield 22
Hebei 22
Norwalk 21
Brussels 20
Falls Church 20
Munich 19
Leawood 17
University Park 17
Beijing 16
Marseille 15
Shanghai 15
Tianjin 14
Augusta 13
Hangzhou 13
Jinan 13
Ottawa 13
Fremont 12
Pune 11
Hong Kong 10
Washington 10
Guangzhou 9
Simi Valley 9
Princeton 8
Zhengzhou 8
Cambridge 7
Changchun 7
Helsinki 7
Jiaxing 7
Busto Arsizio 6
Chicago 6
Detroit 6
Edinburgh 6
Kish 6
Andover 5
Hefei 5
Toronto 5
Bari 4
Costa Mesa 4
Los Angeles 4
Paris 4
Philadelphia 4
Sacramento 4
Ardabil 3
Auburn Hills 3
Brescia 3
Fuzhou 3
Gustavo Adolfo Madero 3
Indiana 3
Latina 3
Modena 3
Omsk 3
Phoenixville 3
Turin 3
Aci Catena 2
Amsterdam 2
Anzio 2
Athens 2
Barcelona 2
Berlin 2
Bologna 2
Bra 2
Chengdu 2
Chongqing 2
Ciampino 2
Clearwater 2
Faenza 2
Fiumicino 2
Formia 2
Totale 3.972
Salva come PNG Salva come JPEG
Nome #
IL PRIVATO SOCIALE: UN'OPPORTUNITÀ PER I PAZIENTI E PER LE STRUTTURE SANITARIE NELL'ATTUALE CONTESTO ECONOMICO 291
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 191
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 170
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 169
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 164
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 159
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 152
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 144
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 142
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 137
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 131
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 124
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 124
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 121
Variability of raltegravir plasma levels in the clinical setting 117
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 116
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 116
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 111
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 107
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 104
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 102
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 102
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 101
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 101
Initial antifungal strategy does not correlate with mortality in patients with candidemia 101
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 100
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 100
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 98
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 98
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 98
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 96
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 96
Effect of aging and human immunodeficiency virus infection on cognitive abilities 93
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 93
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 93
Cognitive reserve and neuropsychological functioning in older HIV-infected people 93
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 92
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 92
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 91
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 91
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 89
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 89
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 89
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 89
Immune response to influenza A(H1N1)v in HIV-infected patients 88
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 88
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 88
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 87
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 86
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 83
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 83
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 82
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 82
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 80
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 77
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 76
Lipid-lowering effect of tenofovir in HIV-infected patients 74
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 73
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 72
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 72
Immune response to influenza A(H1N1)v in HIV-infected patients 71
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 71
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 70
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 70
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 69
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 66
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 63
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort 62
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 58
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 58
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 58
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 53
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 52
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 50
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 49
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 42
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 41
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 34
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 30
Totale 7.535
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.340
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.340
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019171 0 0 0 0 0 0 0 0 0 46 83 42
2019/2020955 226 46 64 33 86 103 49 44 69 61 93 81
2020/2021696 41 86 7 74 85 37 76 16 115 22 121 16
2021/2022806 77 64 25 61 47 40 21 129 29 73 121 119
2022/20231.639 237 261 132 258 136 191 29 145 186 11 39 14
2023/2024802 41 231 30 106 45 212 68 22 30 17 0 0
Totale 7.535